Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

By M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti, S. Gamba, E. Daina, Chiara Fenili, F. Castelletti, Annalisa Sorosina and 8 more. American Society of Nephrology. Clinical Journal, 2010

992 citations recorded by the source corpus.

Subfields: Endocrinology, Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/13b7e9ab4f85c121f9307d72d475d8b74c8f1f4d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. P. Zipfel

Citations in the corpus

• Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. (2017, background): “Genetic makeup also influences disease progression, response to therapies, and recurrence after transplantation (Supplementary Table S5).(56,72,73) C3G, in contrast, appears mechanistically more complex than aHUS, with massive C3 activation in plasma and complement dysregulation on surfaces, includi”
• Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. (2013, neutral): “3 Median follow-up (months) (1-493) (1-353) (1-163) (1-353) (1-75) (1-250) ( 13-444) (4-177) (90-398) (17-213) (1-220) (2-150)”
• Complement System Part II: Role in Immunity (2015, background): “Altogether complement-associated abnormalities are found in about 60% of the aHUS patients (226, 227).”